RESYNC One-Year Meeting in Turin

The RESYNC project, a European Innovation Council-funded consortium coordinated by the Pereira lab, gathered in Turin (IT) last Feb 7th, for a full day of exciting scientific discussions, marking one year after its kick-off.

The RESYNC project aims to use small molecule-based reprogramming to change the function of cells.  Small molecules are ideal candidates for chemical cell reprogramming due to their small size and cost-effective production and scale-up. The goal is to identify the combination of small molecules that effectively reprogram cancer cells into dendritic cells, ultimately bypassing some of the barriers of available immunotherapies.

The event brought together the consortium partners from Asgard Therapeutics (SE), Karolinska Institute (SE), Politecnico di Torino (IT), IOCB Prague (CZ), and Babeș-Bolyai University (RO) for project progress updates, insightful discussions, and future planning, as we continue our collaborative effort to turn cancer cells into immune cells with chemical reprogramming. 

This project has received funding from the European Innovation Council as an EIC Pathfinder Open call with GA 101130218, Title: “Functional chemical reprogramming of cancer cells to induce antitumor immunity”